Recombinant ROR1 & ROR2 Proteins

ROR family includes receptor tyrosine kinases ROR1 and ROR2. ROR1 is of particular interest to the pharmaceutical community, because its expression is only observed in embryonic and cancerous cells, but not in health adult tissues. This feature makes it an ideal drug target for several cancer types. Multiple ROR1-targeted therapies are underdevelopment, including Oncternal's Cirmtuzumab.

The extracellular domain of ROR1 is made of three distinct domains, an immunoglobulin-like (Ig) domain, a frizzled domain, and a kringle domain (Borcherding et al., 2014). Interestingly, antibodies targeting different domains demonstrate a marked difference in therapeutic efficacy when used to treat leukemia cell lines (Daneshmanesh et al., 2013).



ACROBiosystems provides a comprehensive panel of human ROR1 proteins, including product of each single domain, and the entire ECD of all three domains.

Molecule	Cat. No.	Structure
Ig-like	RO1-H5221	Ig-like (39-151) Fzd Kringle His
Frizzled	RO1-H5222	Ig-like Fzd (165-305) Kringle His
Kringle	RO1-H5223	Ig-like Fzd Kringle (308-395) His
Full ECD	RO1-H522y	Ig-like Fzd Kringle His

Recombinant ROR1 & ROR2 Proteins

In addition, we also have biotinylated ROR1-Fc (full ECD), along with mouse and rat ROR1 protein for your assay development.

Molecule	Cat. No	Species	Structure	Size
ROR1	RO1-H82F4	Human	ROR1 (30-403) Fc Avi	25ug, 200ug
ROR1	RO1-H5250	Human	ROR1 (30-403) Fc	200ug, 1mg
ROR1	RO1-M5221	Mouse	ROR1 (30-403) His	100ug, 1mg
ROR1	RO1-M5250	Mouse	ROR1 (30-403) Fc	100ug, 1mg
ROR1	RO1-R5221	Rat	ROR1 (30-403) His	100ug, 1mg

We also have a complementary set of ROR2 proteins for testing cross-reactivity of anti-ROR1 reagent.

Molecule	Cat. No	Species	Structure	Size
ROR2	RO2-H52E5	Human	ROR2 (34-403) His	50ug, 1mg
ROR2	RO2-H5251	Human	ROR2 (34-403) Fc	50ug, 1mg

References

Borcherding, N., Kusner, D., Liu, G.-H., and Zhang, W. (2014). ROR1, an embryonic protein with an emerging role in cancer biology. Protein Cell 5, 496–502.

Daneshmanesh, A.H., Porwit, A., Hojjat-Farsangi, M., Jeddi-Tehrani, M., Tamm, K.P., Grandér, D., Lehmann, S., Norin, S., Shokri, F., Rabbani, H., et al. (2013).Orphan receptor tyrosine kinases ROR1 and ROR2 in hematological malignancies. Leuk. Lymphoma 54, 843–850.

+ 1 800-810-0816 (US/Canada/EU)
+ 86 400-682-2521 (Asia & Pacific)
techsupport@acrobiosystems.com
www.acrobiosystems.com
1 Innovation Way,
Newark, DE 19711